Geoffrey Raymond Oxnard MD

Instructor in Medicine, Dana-Farber Cancer Institute

830 Harrison AveMoakley 3RD FoorBoston, MA 02118
Phone+1 617-638-6428
Fax+1 617-638-5756

Dr. Oxnard is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Oxnard's full profile Already have an account?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2005 - 2008
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2007 - 2027
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020
NY State Medical License 2008 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Afatinib With CT and RT for EGFR-Mutant NSCLC
ACTIVE_NOT_RECRUITING
PHASE2
INHERIT EGFR - Studying Germline EGFR Mutations Start of enrollment: 2012 Dec 28
ACTIVE_NOT_RECRUITING
Sunitinib in Never-Smokers With Lung Adenocarcinoma
COMPLETED
PHASE2

Publications & Presentations

PubMed

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.
Filippo G Dall'Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia, Kristi Beshiri
Clinical Cancer Research. 2026-07-13
Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer.
Justin Battaglini, Maha AlDoughaim, Katie Li, Jasmine Patel, Sita Bhatt
Clinical & Translational Oncology. 2026-06-01
Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy.
Rachel B Keller-Evans, Zoe Fleischmann, Smruthy Sivakumar, Radwa Sharaf, Erik A Williams
The Journal of Molecular Diagnostics. 2026-03-01

Journal Articles

Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small Cell Lung Cancer
G R Oxnard, G M Blumenthal, P G Kluetz, R Pazdur, Annals of Oncology
Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer Population
Khanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation

Lectures

Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis.
2019 ASCO Annual Meeting - 6/1/2019
SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung c...
2019 ASCO Annual Meeting - 6/1/2019
Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

Retired 78-Year-Old Flight Attendant’s Nagging Cough Led to Stage 4 Lung Cancer That Spread to Her BrainDecember 2nd, 2025
Illumina Posts 78% Revenue Growth as Cancer, DNA Testing Ramp Back UpAugust 6th, 2021
Famed Chef Ming Tsai, Whose Spouse Polly Is A Lung Most Cancers Survivor, Introduces A New Tasty Vegan Dish with A Artful Title; How Diet Impacts Well BeingAugust 1st, 2021